Pharmacologic Reversal Agents

  • James F. Gilmore
  • Michael J. Schontz
  • Kenneth E. LupiJr.


Management of antithrombotic and anticoagulant therapy in patients undergoing dental procedures involves balancing the risks of thrombosis and bleeding. Variability in mechanism of action of commonly employed outpatient anticoagulant medications has increased over the past several years. While many patients may be able to have dental procedures performed on therapeutic anticoagulant therapy, providers must be aware of specific supportive care and reversal techniques to match each patient’s individual scenario. An overview of commonly employed and anticipated FDA-approved anticoagulant reversal agents, including indications and dosing, is provided.


Anticoagulant Reversal Vitamin K antagonist Direct oral anticoagulant 


  1. 1.
    Perry DJ, Noakes TJ, Helliwell PS. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203(7):389–93.PubMedCrossRefGoogle Scholar
  2. 2.
    American Red Cross (2017) Blood facts and statistics. Available from: Scholar
  3. 3.
    Garcia DA, Crowther MA. Reversal of warfarin: case-based practice recommendations. Circulation. 2012;125(23):2944–7.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160S–98S.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):7S–47S.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Vigue B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage – from theory to practice. Crit Care. 2009;13(2):209.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126(1):133–9.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e89S–119S.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician. 2011;83(6):719–24.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Lee K, Istl A, Dubois L, DeRose G, Forbes TL, Wiseman D, et al. Fibrinogen level and bleeding risk during catheter-directed thrombolysis using tissue plasminogen activator. Vasc Endovasc Surg. 2015;49(7):175–9.CrossRefGoogle Scholar
  11. 11.
    Warmuth M, Mad P, Wild C. Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand. 2012;56(5):539–48.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Behring CLS. RiaSTAP® [prescribing information]. Kankakee, IL: Behring CLS; 2016.Google Scholar
  13. 13.
    Aiyagari V. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery. 2006;59(5):E1152. author reply EPubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Desmopressin [database on the Internet]. Gold Standard, Inc. Available from:
  15. 15.
    Gahart B. Intravenous medications. St. Louis, MO: Mosby; 1999.Google Scholar
  16. 16.
    McEnvoy G. American hospital formulary service. American Society of Hospital Pharmacists: Bethesda, MD; 2000.Google Scholar
  17. 17.
    Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol. 1994;69(4):173–80.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Baglin T. Drugs and haemostasis. In: Bowes JCF, editor. Clinical pharmacology. 11th ed. London: Churchill Livingstone; 2012. p. 482–95.CrossRefGoogle Scholar
  19. 19.
    Teng R, Mitchell PD, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. J Clin Pharm Ther. 2014;39(2):186–91.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Galvez A, Gomez-Ortiz G, Diaz-Ricart M, Escolar G, Gonzalez-Sarmiento R, Zurbano MJ, et al. Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost. 1997;77(5):975–80.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Raimondi P, Hylek EM, Aronis KN. Reversal agents for oral antiplatelet and anticoagulant treatment during bleeding events: current strategies. Curr Pharm Des. 2016;23(9):1406–23.CrossRefGoogle Scholar
  22. 22.
    Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood. 1988;72(5):1449–55.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Mannucci PMVV, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986;67:1148–53.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Kim JH, Baek CH, Min JY, Kim JS, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol. 2015;94(9):1457–61.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Leithauser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39(1-4):293–302.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood. 2003;102(13):4594–9.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Agerso H, Seiding Larsen L, Riis A, Lovgren U, Karlsson MO, Senderovitz T. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004;58(4):352–8.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308(1):8–12.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3(3):138–53.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kohler M, Hellstern P, Tarrach H, Bambauer R, Wenzel E, Jutzler GA. Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. Haemostasis. 1989;19(1):38–44.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Watson AJ, Keogh JA. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron. 1982;32(1):49–52.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Ferring Pharmaceuticals I. DDAVP (desmopressin acetate) injection [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals I; 2014.Google Scholar
  33. 33.
    Sanofi-Aventis. DDAVP nasal spray (desmopressin acetate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2015.Google Scholar
  34. 34.
    CLS Behring. Stimate (desmopressin acetate) intranasal [prescribing information]. King of Prussia, PA: CLS Behring; 2013.Google Scholar
  35. 35.
    Pharmaceuticals A. Protamine sulfate IV injection [prescribing information]. Schaumburg, IL: Pharmaceuticals A; 2008.Google Scholar
  36. 36.
    Sanofi-Aventis US L. LOVENOX(R) IV, SC injection, enoxaparin sodium IV, SC injection [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US L; 2008.Google Scholar
  37. 37.
    Phytonadione, Vitamin K1 [database on the Internet]. Gold Standard, Inc. [cited February 8th, 2017]. Available from:
  38. 38.
    Merck. AquaMephyton (phytonadione, vitamin K1) [prescribing information]. Whitehouse Station, NJ: Merck; 2002.Google Scholar
  39. 39.
    Merck. Mephyton (phytonadione, vitamin K1) [prescribing information]. Whitehouse Station, NJ: Merck; 2004.Google Scholar
  40. 40.
    Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S–84S.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):204S–33S.PubMedCrossRefGoogle Scholar
  42. 42.
    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e44S–88S.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Wilson MD, Davis JE. Antithrombotic reversal agents. Emerg Med Clin North Am. 2014;32(3):715–25.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;4(9):1853–63.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115(1):145–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166(4):391–7.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002;137(4):251–4.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med. 1998;158(19):2136–40.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999;159(22):2721–4.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis. 2001;11(2):175–83.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Patriquin C, Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol. 2011;4(6):657–65. quiz 66–7PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis. 2007;24(2):93–7.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy. 2000;20(10):1159–66.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469–73.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S–50S.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    NovoNordisk. NovoSeven® RT (recombinant factor VIIa) [prescribing information]. Plainsboro, NJ: NovoNordisk; 2014.Google Scholar
  57. 57.
    American Society of Health-System Pharmacists. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2010.Google Scholar
  58. 58.
    Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154(8):529–40.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Barton CA, Johnson NB, Case J, Warden B, Hughes D, Zimmerman J, et al. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa. Am J Emerg Med. 2015;33(11):1562–6.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    DeLoughery E, Avery B, DeLoughery TG. Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient. Am J Hematol. 2016;91(7):705–8.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;2(3):263–7.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Dixit D, Thomas Z. Letter by Dixit and Thomas regarding article, “Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association”. Stroke. 2015;46(11):e236.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39(3):395–402.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014;111(5):989–95.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–24.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost. 2013;110(1):162–72.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168(4):4228–33.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33(4):883–90.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791–800.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ. 2011;183(1):E9–19.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6–46.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Behring CLS. KCENTRA(R) intravenous injection lyophilized powder for solution, prothrombin complex concentrate human intravenous injection lyophilized powder for solution [prescribing information]. Kankakee, IL: Behring CLS; 2014.Google Scholar
  73. 73.
    Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–43.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99(3):251–60.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Joseph R, Burner J, Yates S, Strickland A, Tharpe W, Sarode R. Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. Transfusion. 2016;56(4):799–807.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116(3):619–24.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622–31.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37(6):1465–70.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;23(7):972–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37(1):151–5.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77(3):477–80.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171–7.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Tilton R, Michalets EL, Delk B, Sutherland SE, Ramming SA. Outcomes associated with prothrombin complex concentrate for international normalized ratio reversal in patients on oral anticoagulants with acute bleeding. Ann Pharmacother. 2014;48(9):1106–19.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Imberti D, Magnacavallo A, Dentali F, Condoleo E, Gallerani M, Benedetti R, et al. Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding. J Thromb Thrombolysis. 2013;36(1):102–8.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Switzer JA, Rocker J, Mohorn P, Waller JL, Hughes D, Bruno A, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke. 2012;43(9):2500–2.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Kantorovich A, Fink JM, Militello MA, Wanek MR, Smedira NG, Soltesz EG, et al. Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. Ann Pharmacother. 2015;49(8):876–82.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Mangram A, Oguntodu OF, Dzandu JK, Hollingworth AK, Hall S, Cung C, et al. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants? J Crit Care. 2016;33:252–6.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L. 3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis. 2016;42(1):19–26.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Al-Majzoub O, Rybak E, Reardon DP, Krause P, Connors JM. Evaluation of warfarin reversal with 4-factor prothrombin complex concentrate compared to 3-factor prothrombin complex concentrate at a tertiary academic medical center. J Emerg Med. 2016;50(1):7–13.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Stewart WS, Pettit H. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding. Am J Emerg Med. 2013;31(8):1251–4.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009;2(4):217–25.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Dentali F, Marchesi C, Giorgi Pierfranceschi M, Crowther M, Garcia D, Hylek E, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thrombosis and haemostasis. 2011;106(3):429–38.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011;9(9):1705–12.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis. 2014;37(2):217–33.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Curto A, Albaladejo A, Alvarado A. Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran. J Clin Exp Dent. 2017;9(2):e289–e93.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Idarucizumab [database on the Internet]. Gold Standard, Inc. [cited 8 Feb 2017]. Available from:
  98. 98.
    Boehringer Ingelheim Pharmaceuticals I. Praxbind (Idarucizumab) injection [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals I; 2015.Google Scholar
  99. 99.
    Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–62.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–51.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413–24.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Curto A, Albaladejo A. Implications of apixaban for dental treatments. J Clin Exp Dent. 2016;8(5):e611–e4.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Curto A, Curto D, Sanchez J. Managing patients taking edoxaban in dentistry. J Clin Exp Dent. 2017;9(2):e308–e11.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–41.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Crowther MLG, Lu G, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood. 2014;124(21):4269.Google Scholar
  108. 108.
    Crowther MVM, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064446), an antidote for fXa inhibitors. Blood. 2013;122:3636.Google Scholar
  109. 109.
    Crowther MLT, Mathur V, et al. A phase 2 randomized double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013;11(suppl):1322.Google Scholar
  110. 110.
    Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–42.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematology Am Soc Hematol Educ Program. 2012;2012:529–35.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Kor DJ, Gajic O. Blood product transfusion in the critical care setting. Curr Opin Crit Care. 2010;16(4):309–16.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • James F. Gilmore
    • 1
  • Michael J. Schontz
    • 2
  • Kenneth E. LupiJr.
    • 2
  1. 1.Department of PharmacyCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Department of PharmacyBrigham and Women’s HospitalBostonUSA

Personalised recommendations